Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of sacituzumab govitecan versus physician's choice chemotherapy in advanced urothelial cancer
2024-513870-23-00Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in transitional cell carcinoma (TCC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Overall survival. Started Oct 2024; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-513870-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513870-23-00.